The Influence of Age and Gender on the Pharmacokinetics of Moxifloxacin

[1] Dalhoff A.(1996) activity of BAY 12-8039, a new 8-methoxyquinolone Chemotherapy 42 410-25

[2] Petersen U.(1997)In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Antimicrob Agents Chemother 41 1594-7

[3] Endermann R.(1997), and J Chromatogr B Biomed Sci Appl 702 163-74

[4] Brueggemann A.B.(1993)Determination of BAY 12-8039, a new 8-methoxyquinolone, in human body fluids by high-performance liquid chromatography with fluorescence detection using on-column focusing Antimicrob Agents Chemother 37 1073-81

[5] Kugler K.C.(1993)Pharmacodynamics of intravenous Ciprofloxacin in seriously ill patients Antimicrob Agents Chemother 37 234-9

[6] Doern G.V.(1982)Evaluation of the efficacy of Ciprofloxacin against New Engl J Med 306 1081-8

[7] Stass H.(1997) by using a mouse protection model Clin Microbiol Infection 3 87-5

[8] Dalhoff A.(1997)Drug disposition in old age Clin Microbiol Infection 3 87-undefined

[9] Forrest A.(1998)Pharmacokinetics, safety, and tolerability of 600 mg BAY 12-8039 administered once daily over 10 days [abstract no. P387]. 8thEuropean Congress of Clinical Microbiology and Infectious Diseases; 1997 May 25–28; Lausanne, Switzerland Antimicrob Agents Chemother 42 2060-undefined

[10] Nix D.E.(undefined)Pharmacokinetics, safety, and tolerability of 800 mg BAY 12-8039 administered orally as a single dose [abstract no. P388]. 8th European Congress of Clinical Microbiology and Infectious Diseases; 1997 May 25–28; Lausanne, Switzerland undefined undefined undefined-undefined

[1] Dalhoff A.(1996) activity of BAY 12-8039, a new 8-methoxyquinolone Chemotherapy 42 410-25

[2] Petersen U.(1997)In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Antimicrob Agents Chemother 41 1594-7

[3] Endermann R.(1997), and J Chromatogr B Biomed Sci Appl 702 163-74

[4] Brueggemann A.B.(1993)Determination of BAY 12-8039, a new 8-methoxyquinolone, in human body fluids by high-performance liquid chromatography with fluorescence detection using on-column focusing Antimicrob Agents Chemother 37 1073-81

[5] Kugler K.C.(1993)Pharmacodynamics of intravenous Ciprofloxacin in seriously ill patients Antimicrob Agents Chemother 37 234-9

[6] Doern G.V.(1982)Evaluation of the efficacy of Ciprofloxacin against New Engl J Med 306 1081-8

[7] Stass H.(1997) by using a mouse protection model Clin Microbiol Infection 3 87-5

[8] Dalhoff A.(1997)Drug disposition in old age Clin Microbiol Infection 3 87-undefined

[9] Forrest A.(1998)Pharmacokinetics, safety, and tolerability of 600 mg BAY 12-8039 administered once daily over 10 days [abstract no. P387]. 8thEuropean Congress of Clinical Microbiology and Infectious Diseases; 1997 May 25–28; Lausanne, Switzerland Antimicrob Agents Chemother 42 2060-undefined

[10] Nix D.E.(undefined)Pharmacokinetics, safety, and tolerability of 800 mg BAY 12-8039 administered orally as a single dose [abstract no. P388]. 8th European Congress of Clinical Microbiology and Infectious Diseases; 1997 May 25–28; Lausanne, Switzerland undefined undefined undefined-undefined